Louisville, Colorado, United States
Strategy-minded people leader determined to eradicate disease through the development and commercialization of groundbreaking treatments. 20+ year track record of success in strategy, business development, information technology, marketing, sales, account management, finance, product development and market research.
At RefinedScience, a joint venture between CU Anschutz and UCHealth, we leverage technology, expertise and deep clinical/biological datasets to conquer complex diseases. I lead corporate development and strategy initiatives that drive growth and innovation. • Developed a comprehensive strategy to utilize RS's de-risking platform to form new clinical-stage biotech ventures. • Identified a pipeline of acquisition opportunities in heme/oncology, and successfully negotiated the acquisition of a lead drug candidate for a new clinical stage biotech company.
Developed campus-wide strategy to leverage de-identified longitudinal clinical and biological datasets for research purposes. Led the creation of a clinical stage heme/oncology biotech company based on an in-licensed asset.
Leading Business Development for CU Innovations. CUI translates discovery into impact through transparent, flexible, best practice intellectual property management services. Located on the University of Colorado Anschutz Medical Campus, CUI provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.
Interim role leading the West Regional field team through a company-wide restructuring.
Promoted to Sr. Division Manager. Led division team through successful cancer immunotherapy launches in ES-SCLC, 1L NSCLC and TNBC. Also, as Account Team Lead, leading cross-BioOncology team servicing a major community oncology account.
Developed marketing strategies and tactics to support TECENTRIQ launches in Small Cell Lung Cancer, Triple Negative Breast Cancer, and 1L NSCLC, contributing to a more than doubling of sales year over year.
Led commercial launch planning for a genetically-tailored therapy for heart failure.
Led due diligence and deal structuring efforts, culminating in the strategic sale of the company to Cardiovascular Systems, Inc.
Led commercial launch planning, developed target product profiles for pipeline programs, and evaluated in-licensing opportunities.